Perrigo Prioritizes Innovating First After Following OTC Brands To Market
Executive Summary
Perrigo’s "national brand better" approach includes adding "better" value to generic equivalents that branded aren't offering, says President and CEO Murray Kessler. Prevacid 24 HR acquisition puts Perrigo at top of 15-mg lansoprazole PPI brand sales as well as in the generics market.
You may also be interested in...
Perrigo’s Pivot To Building Brand Market Share Boosted With Opill OTC Oral Contraceptive Approval
Year after acquiring HRA, Perrigo makes preparations to launch arguably the most anticipated OTC switch in US pharma history, Opill with 0.075-mg norgestel. Analysts estimate $100m annual market for OTC birth control.
First OTC Birth Control Pill Approved In US Will Launch With Three-Year Market Exclusivity
FDA approval of Perrigo subsidiary HRA’s application comes 60 years after Rx birth control was approved in the US, one year after the application was submitted, and 13 months after the Supreme Court’s Dobbs ruling. Perrigo plans to launch sales in 2024 first quarter.
First OTC Birth Control Pill Approved In US Will Launch With Three-Year Market Exclusivity
FDA approval of Perrigo subsidiary HRA’s application comes 60 years after Rx birth control was approved in the US, one year after the application was submitted, and 13 months after the Supreme Court’s Dobbs ruling. Perrigo plans to launch sales in 2024 first quarter.